US FDA Coronavirus Response Features Three-Step Triage Process For Inquiries
Office of New Drugs Director Peter Stein outlines how his reviewers are prioritizing COVID-19 work, and how he is reallocating resources to the pandemic response.
Office of New Drugs Director Peter Stein outlines how his reviewers are prioritizing COVID-19 work, and how he is reallocating resources to the pandemic response.